News

Published on 17 Nov 2021 on Benzinga via Yahoo Finance

EyePoint Pharmaceuticals Raises $100M Via Capital Raise At 5% Discount


Article preview image

EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has priced an underwritten public offering of 4.03 million at .75 per share and pre-funded warrants to purchase up to an aggregate of 3.27 million shares at $13.74 per pre-funded warrant.The offer price represents a discount of 5% from the last close price of $14.50 on Tuesday.The aggregate gross proceeds from this offering are expected to be approximately $100.3 million.Underwriters have an option to purchase up to an additional 1.09 million shares.The offering will close by November 19.Cowen and Guggenheim Securities are acting as joint book-running managers for the offering.EyePoint will use the proceeds to advance EYP-1901, support earlier stage pipeline development initiatives and general corporate purposes.Recently, the Company announced encouraging six-month interim data from the Phase 1 trial of EYP-1901 in wet age-related macular degeneration.Price Action: EYPT shares are up 3.20% at $14.50 during the premarket session on the last check Wednesday.

See more from Benzinga

NASDAQ.EYPT price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Slashed This Year's Revenue Estimates By...

One thing we could say about the analysts on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) - they ...

Simply Wall St. via Yahoo Finance 9 Mar 2024

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Q4 2023 Earnings Call Transcript March 7, 2024 EyePo...

Insider Monkey via Yahoo Finance 8 Mar 2024

EyePoint Pharmaceuticals Inc (EYPT) Reports Growth Amidst Strategic Shifts in Q4 and Full-Year 2023

Total Net Revenue: Increased to $14.0 million in Q4 2023 from $10.5 million in Q4 2022.Net Produc...

GuruFocus.com via Yahoo Finance 7 Mar 2024

EyePoint Pharmaceuticals appoints new Chief Medical Officer

EyePoint Pharmaceuticals appoints new Chief Medical Officer

Investing.com 4 Mar 2024

EyePoint Pharmaceuticals Inc SVP & Chief Commercial Officer David Jones Sells 26,017 Shares

On January 26, 2024, David Jones, SVP & Chief Commercial Officer of EyePoint Pharmaceuticals Inc ...

GuruFocus.com via Yahoo Finance 28 Jan 2024

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 71% Above Its Share...

Key Insights The projected fair value for EyePoint Pharmaceuticals is US$38.94 based on 2 Stage F...

Simply Wall St. via Yahoo Finance 14 Jan 2024

EyePoint Pharmaceuticals Inc's Chief Medical Officer Dario Paggiarino Sells 22,913 Shares

EyePoint Pharmaceuticals Inc (NASDAQ:EYPT), a specialty pharmaceutical company, focuses on develo...

GuruFocus.com via Yahoo Finance 11 Jan 2024

What EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 194% Share Price Gain Is Not Telling You

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholders would be excited to see that the share ...

Simply Wall St. via Yahoo Finance 18 Dec 2023

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Trimmed Their Revenue Forecasts By 11%

Market forces rained on the parade of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shareholders t...

Simply Wall St. via Yahoo Finance 13 Dec 2023

Institutional investors have a lot riding on EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) with 43%...

Key Insights Institutions' substantial holdings in EyePoint Pharmaceuticals implies that they hav...

Simply Wall St. via Yahoo Finance 11 Dec 2023